Politics & Current AffairsDon't let Supreme Court news distract you from the FDA appointment.
By schuhplattler Comments: 3037, member since Sat Dec 23, 2006
On Wed Feb 17, 2016 06:23 AM
Oppose the nomination of Dr. Robert Califf as head of the Food and Drug Administration. At a time of rising prescription drug prices and safety risks we need a champion for American families, not an insider so closely tied to the pharmaceutical industry.
A final Senate vote on Califf is expected within days. This is our last chance.
Relationships with the pharmaceutical industry:
Califf worked very closely with pharmaceutical companies at the Duke clinical trials center "convincing them to do large, expensive, and, for Duke, profitable clinical trials." He was a paid consultant for Merck Sharp & Dohme, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, and Eli Lilly per ProPublica from 2009 to 2013. The largest consulting payment was $87,500 by Johnson & Johnson in 2012, and "most of funds for travel or consulting under $5,000", which has been called "minimal for a physician of his stature". From 2013-2014 he was paid a total of $52,796, the highest amount was $6,450 from Merck Sharp & Dohme, followed by Amgen, F. Hoffmann-La Roche AG, Janssen Pharmaceutica, Daiichi Sankyo, Sanofi-Aventis, Bristol-Myers Squibb and AstraZeneca. He was the Director of Portola Pharmaceuticals, Inc. from July 2012 to January 26, 2015, Advisor of Proventys, Inc., Chairman of the medical advisory board of Regado Biosciences, Inc. and has been member of the medical advisory board since June 2, 2009, and member of the clinical advisory board of Corgentech Inc. Forbes wrote that his close ties to the drug industry were the reason for him not being nominated for the FDA Commissioner position in 2009.
Numbers in brackets refer to Wiki's own citations.